Novel ADC Target Hunting in Pediatric AML – Module 4

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (4 of 5 Modules)

This activity provides an overview of key data and ongoing clinical trials investigating the development and use of antibody-drug conjugates (ADC) targeting different myeloid markers for the treatment of pediatric acute myeloid leukemia (AML).

0.50 CE Credit(s)
Expires: March 12, 2024

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Assess key data sets and ongoing clinical trials investigating antibody-drug conjugates for the treatment of acute myeloid leukemia (AML)

Activity Faculty

Meshinchi-Faculty Headshot_135x135

Soheil Meshinchi, MD, PhD

Full Member, Fred Hutchinson Cancer Center
Professor, Pediatrics
University of Washington
Seattle, WA

Provider Statement

This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Supporter Statement

The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society.


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources